Jannsen has announced that its
Invokana (canaglifozin), an SGLT2
inhibitor for type 2 diabetes, will
be available on PBS from 1 Dec
following its recent TGA approval
(PD 24 Oct) and earlier FDA
approval (PD 02 Apr).
Another SGLT2 inhibitor will also
be listed on the PBS from next
month: Forxigar (dapagliflozin)
from Astra-Zeneca and Bristol-
Myers Squibb (PD 08 Nov).The above article was sent to subscribers in Pharmacy Daily's issue from 20 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Nov 13
THE vaping reforms bill passed in the Senate this week has raised significant questions around pharmacy insurance premiums, business risks and regulatory compliance for community pharmacists, according to the profession’s peak body.
A COMBINATION of varenicline and nicotine lozenges may be a more effective treatment option for people looking to quit smoking compared to varenicline alone, according to results from a new clinical trial at Monash University.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.